Document is current
Any future updates will be listed below
-
Authors
Óskarsson, Jón Þórir https://orcid.org/0000-0002-9201-1166
Rögnvaldsson, Sæmundur https://orcid.org/0000-0003-2162-8414
Thorsteinsdottir, Sigrun https://orcid.org/0000-0001-5017-3530
Aspelund, Thor
Gunnarsson, Steinar Bragi
Hákonardóttir, Guðlaug Katrín
Sigurðardóttir, Guðrún Ásta
Þórðardóttir, Ásdís Rósa
Gíslason, Gauti Kjartan https://orcid.org/0000-0003-4710-0781
Ólafsson, Andri
Sigurðsson, Jón Kristinn
Eyþórsson, Elías
Jónsson, Ásbjörn
Viðarsson, Brynjar
Önundarson, Páll Torfi
Agnarsson, Bjarni A.
Pálmason, Róbert
Sigurðardóttir, Margrét
Þorsteinsdóttir, Ingunn
Ólafsson, Ísleifur
Harding, Stephen
Flores-Montero, Juan https://orcid.org/0000-0002-1119-4387
Orfao, Alberto https://orcid.org/0000-0002-0007-7230
Durie, Brian G. M.
Love, Thorvardur Jon
Kristinsson, Sigurdur Yngvi https://orcid.org/0000-0002-4964-7476
-
Funding
Funding for this research was provided by:
International Myeloma Foundation (NA)
Icelandic Centre for Research (173857 & 217897-051 & 228521-051)
EC | Horizon 2020 Framework Programme (716677 & 101045549)
Leukemia and Lymphoma Society (2340-23)
Háskóli Íslands (NA)
Landspítali Háskólasjúkrahús (NA)
- License Information
-
More Information
Article History
Received: 20 June 2023
Revised: 15 November 2023
Accepted: 17 November 2023
First Online: 1 December 2023
Competing interests
: SH is an employee of The Binding Site. JFM and AO are listed as (co) inventors on the EuroFlow patent “Methods, reagents and kits for detecting minimal residual disease” (US 11571457), owned by the EuroFlow scientific consortium, which describes the flow cytometry panel used in this study. AO reports to be the chairman of the EuroFlow Scientific Foundation, which receives royalties from licensed patents, which are collectively owned by the participants of the EuroFlow Consortium. These royalties are exclusively used for continuation of the EuroFlow collaboration and sustainability of the EuroFlow consortium. AO reports Educational Services Agreement and a Scientific Advisor Agreement from BD Biosciences (San José, CA). BGMD has done consultancy for Amgen, Janssen, Celgene, Takeda. SYK has received research funding from Amgen and Celgene. The Remaining authors declare no competing interests.
